ABSTRACT Background Peripheral neuropathy (PN) is a common consequence of peripheral nervous system (PNS) disorders, yet its effective treatment remains a significant clinical challenge. Pyroptosis, an inflammatory form of programmed cell death (PCD) triggered by gasdermin A–E (GSDMA‐E), contributes to the pathogenesis of PN and represents a promising therapeutic target. While reviews of pyroptosis in other diseases are extensive, comprehensive reviews focusing on PN are lacking. Method We systematically searched PubMed, Scopus, Web of Science, and Google Scholar (1986–2025). Only original studies investigating pyroptosis in PN were included. Results This review first consolidates established evidence, highlighting a context‐dependent dual role of pyroptosis in PN. Its detrimental effects in chronic pain involve canonical (caspase‐1/GSDMD) or noncanonical pathways (e.g., caspase‐4/5/11/GSDMD, caspase‐3/GSDME, caspase‐8/GSDMC), often initiated by inflammasomes (e.g., NOD‐like receptor family pyrin domain containing 3 NLRP3). Conversely, its beneficial, tumoricidal role is leveraged in neuroblastoma. Preclinically, diverse inhibitors—including NLRP3 inhibitors (e.g., MCC950), caspase‐1 inhibitors (e.g., VX‐765), and P2X7R antagonists (e.g., Brilliant Blue G)—alleviate pain and promote nerve repair, while pyroptosis inducers (e.g., axitinib) combat chemoresistant tumors. We then identify critical knowledge gaps and emerging frontiers. The roles of most gasdermins (GSDMA, GSDMB, GSDMC) in PN are unknown. We explore the emerging concept of PANoptosis (crosstalk among pyroptosis, apoptosis, and necroptosis) as a novel conceptual framework for PNS pathologies, where shared molecular hubs may amplify neuroinflammation. Furthermore, despite promising strategies like combination therapy and drug repurposing, a significant translational gap exists, with no current clinical trials specifically targeting pyroptosis for PN. Conclusion and Perspective Targeting pyroptosis is a novel therapeutic avenue for PN. This review synthesizes current mechanistic understanding, evaluates preclinical therapeutic strategies, and delineates crucial future directions, including elucidating gasdermin diversity, validating PANoptosis, and bridging the translational divide, thereby accelerating their application for patients suffering from PN.
Wei et al. (Thu,) studied this question.